Abstract
The term “sundowning” describes a clinical phenomenon characterized by late afternoon exacerbation of behavioural symptoms in dementia. Beyond this clinical definition, the debate around this concept is not properly solved, because many authors define it in different ways, mentioning various hypothetical etiological explanations. It represents a concrete problem, which is difficult to manage for physicians and caregivers, and is probably linked to various biological, psychological and social aspects. As recently reported, the sundowning phenomenon is a predictor of faster cognitive decline in Alzheimer’s disease, and as such can represent a possible marker of frailty in this illness. This article presents an overview of the biological understanding and possible pharmacological and non-pharmacological treatment of this condition.
Keywords: Alzheimer’s disease, sundowning, frailty, sleep disorder, disrupted circadian rhythm.
CNS & Neurological Disorders - Drug Targets
Title:Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
Volume: 12 Issue: 4
Author(s): Davide Ferrazzoli, Francesco Sica and Giuseppe Sancesario
Affiliation:
Keywords: Alzheimer’s disease, sundowning, frailty, sleep disorder, disrupted circadian rhythm.
Abstract: The term “sundowning” describes a clinical phenomenon characterized by late afternoon exacerbation of behavioural symptoms in dementia. Beyond this clinical definition, the debate around this concept is not properly solved, because many authors define it in different ways, mentioning various hypothetical etiological explanations. It represents a concrete problem, which is difficult to manage for physicians and caregivers, and is probably linked to various biological, psychological and social aspects. As recently reported, the sundowning phenomenon is a predictor of faster cognitive decline in Alzheimer’s disease, and as such can represent a possible marker of frailty in this illness. This article presents an overview of the biological understanding and possible pharmacological and non-pharmacological treatment of this condition.
Export Options
About this article
Cite this article as:
Ferrazzoli Davide, Sica Francesco and Sancesario Giuseppe, Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?, CNS & Neurological Disorders - Drug Targets 2013; 12 (4) . https://dx.doi.org/10.2174/18715273113129990065
DOI https://dx.doi.org/10.2174/18715273113129990065 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Appropriate Antibiotic Prescribing Pattern in Hospitalized Children
Current Drug Safety Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety Total Polyphenols and Bioactivity of Seeds and Sprouts in Several Legumes
Current Pharmaceutical Design Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Thienopyridines and Statins: Assessing a Potential Drug-Drug Interaction
Current Pharmaceutical Design Omega-3 Fatty Acids and the Expression of Membrane Proteins: Emphasis on Molecules of Immunologic Importance.
Current Organic Chemistry Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]
Current Vascular Pharmacology Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism The Accuracy of Self-Reported Hypertension: A Systematic Review and Meta-Analysis
Current Hypertension Reviews CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation